



November 2013, Lisboa, Portugal

Vibeke Halkjær-Knudsen, PhD, Senior Biosafety & Biosecurity Officer

Director Department of EHS

Statens Serum Institute (SSI), Denmark

International Biological Threat Reduction,

Sandia National Laboratories, Albuquerque, New Mexico

SSI's MISSION STATEMENT

**Prevention and Control of Infectious Diseases,
Biological Threats and Congenital Disorders**

Infectious
Disease Control

Vaccine
Production



Diagnostic
Services

Diagnostic
Products

25 Acres
Founded in 1902
1,600 Employees in total
Annual turnover 1.5 Billion DKK



My Background



2004

IPV * facility

* IPV: Inactivated Polio Virus



- **Develop new nonanimal process**
- **Upscale from pilot plant to large scale production**
- **Merge GMP and Biosafety**
- **Building a BSL2 going to 4**

My experience

Predominantly
from
containment
projects

Tight
Decon

BSL Biosafety level

GMO – genetically modified
organisms

GMP – Good manufacturing
practice



Polio Vaccine Facility
GMP, BSL3^{enhanced}
1999 - 2004



Animal Facility
BSL2, BSL3, GMO1
2003 – 2005

2006 - 2010


Pertussis Vaccine Facility
Multi Purpose Plant
GMP, BSL2, GMO1
2004 - 2006



Metrics



- \$ 25 mio
- 1500 m²
- 4 legal proceedings, solved by negotiations
- 2½ year delayed, 5% above budget



- \$ 20 mio
- 1500 m²
- 3 legal proceedings, solved 2 days before court
- 5 years delayed & extra \$ 10 mio (BSL3 area)



- \$ 40 mio
- 2500 m²
- Lots of discussions and arguments
- On time, on budget